Phase II trial of S-1 as third-line or further chemotherapy in patients with advanced non-small-cell lung cancer
- 18 February 2014
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 19 (6) , 1005-1010
Abstract
This study was conducted to evaluate the efficacy and safety of S-1 in patients with advanced non-small-cell lung cancer (NSCLC), receiving two or more prior chemotherapy regimens.Keywords
This publication has 22 references indexed in Scilit:
- Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancerLung Cancer, 2011
- Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung CancerJournal of Thoracic Oncology, 2011
- Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancerInternational Journal of Clinical Oncology, 2010
- Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database SurveyJournal of Thoracic Oncology, 2010
- Efficacy of S-1 monotherapy for non-small cell lung cancer after the failure of two or more prior chemotherapy regimensOncology Letters, 2010
- Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in JapanAnnals of Oncology, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in ratsCancer Chemotherapy and Pharmacology, 1996